HealthInvest Partners AB Buys New Shares in Edwards Lifesciences Co. (NYSE:EW)

HealthInvest Partners AB acquired a new position in Edwards Lifesciences Co. (NYSE:EW - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 20,815 shares of the medical research company's stock, valued at approximately $1,587,000. Edwards Lifesciences accounts for approximately 1.3% of HealthInvest Partners AB's holdings, making the stock its 23rd biggest holding.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Castleview Partners LLC purchased a new stake in Edwards Lifesciences in the 1st quarter worth $25,000. Compass Wealth Management LLC bought a new position in Edwards Lifesciences during the fourth quarter valued at approximately $31,000. Turtle Creek Wealth Advisors LLC purchased a new position in Edwards Lifesciences during the 4th quarter valued at approximately $34,000. Jackson Grant Investment Advisers Inc. bought a new stake in Edwards Lifesciences in the 3rd quarter worth approximately $38,000. Finally, Janiczek Wealth Management LLC raised its holdings in shares of Edwards Lifesciences by 108.6% during the 3rd quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company's stock worth $40,000 after acquiring an additional 303 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Up 1.0 %

NYSE:EW traded up $0.86 during midday trading on Tuesday, reaching $90.06. 2,640,500 shares of the stock traded hands, compared to its average volume of 3,888,942. The business has a 50-day moving average of $90.07 and a two-hundred day moving average of $77.92. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The stock has a market capitalization of $54.21 billion, a PE ratio of 38.78, a price-to-earnings-growth ratio of 4.47 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, meeting the consensus estimate of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same quarter in the prior year, the business posted $0.64 EPS. The business's revenue for the quarter was up 13.3% compared to the same quarter last year. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the subject of several research reports. Truist Financial increased their price objective on shares of Edwards Lifesciences from $78.00 to $84.00 and gave the company a "buy" rating in a research report on Friday, December 22nd. Wells Fargo & Company upgraded Edwards Lifesciences from an "equal weight" rating to an "overweight" rating and set a $94.00 price target for the company in a research report on Friday, February 2nd. Royal Bank of Canada upped their price objective on Edwards Lifesciences from $95.00 to $101.00 and gave the company an "outperform" rating in a research report on Monday. OTR Global raised Edwards Lifesciences from a "mixed" rating to a "positive" rating in a research note on Tuesday, March 26th. Finally, Oppenheimer boosted their target price on Edwards Lifesciences from $93.00 to $100.00 and gave the company an "outperform" rating in a research report on Monday, March 18th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $91.73.

Insider Activity at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CFO Scott B. Ullem sold 7,255 shares of the company's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the sale, the chief financial officer now directly owns 19,248 shares of the company's stock, valued at approximately $1,506,925.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Heisz Leslie Stone sold 7,056 shares of the firm's stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $86.45, for a total transaction of $609,991.20. Following the transaction, the director now directly owns 26,980 shares of the company's stock, valued at approximately $2,332,421. The disclosure for this sale can be found here. Insiders sold 194,004 shares of company stock valued at $17,166,254 in the last three months. 1.27% of the stock is owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.